BrainsWay (NASDAQ:BWAY) Earns Buy Rating from HC Wainwright

BrainsWay (NASDAQ:BWAY)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $16.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 56.71% from the company’s previous close.

BrainsWay Trading Down 0.9 %

Shares of NASDAQ BWAY opened at $10.21 on Wednesday. The stock has a fifty day moving average price of $10.25 and a 200 day moving average price of $9.59. The company has a market cap of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. BrainsWay has a 12-month low of $4.61 and a 12-month high of $11.79.

Institutional Trading of BrainsWay

Several large investors have recently modified their holdings of the business. Valor Management LLC acquired a new stake in shares of BrainsWay during the fourth quarter valued at about $19,838,000. Phoenix Financial Ltd. grew its stake in shares of BrainsWay by 100.8% during the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock valued at $4,552,000 after acquiring an additional 242,366 shares in the last quarter. ARK Investment Management LLC bought a new position in shares of BrainsWay during the fourth quarter worth about $1,656,000. MYDA Advisors LLC lifted its position in shares of BrainsWay by 100.2% during the fourth quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock worth $1,133,000 after purchasing an additional 60,100 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of BrainsWay by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after purchasing an additional 1,786 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.